Businesses
Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
Real-World Head-To-Head Analysis Shows 51% Reduction in Risk of Death for Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Erleada Versus Darolutamide Without Docetaxel Through 24 Months
RARITAN, New Jersey, Feb. 3 -- Johnson and Johnson Innovative Medicine issued the following news release on Feb. 2, 2026:* * *
Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA(R) (apalutamide) versus darolutamide without docetaxel through 24 months
First ever head-to-head analysis compares overall survival outcomes of ERLEADA(R) versus darolutamide
Retrospective study reinforces real-world efficacy of ERLEADA(R) for patients with mCSPC
*
HORSHAM, PA - Johnson & Johnson today announced ... Show Full Article RARITAN, New Jersey, Feb. 3 -- Johnson and Johnson Innovative Medicine issued the following news release on Feb. 2, 2026: * * * Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA(R) (apalutamide) versus darolutamide without docetaxel through 24 months First ever head-to-head analysis compares overall survival outcomes of ERLEADA(R) versus darolutamide Retrospective study reinforces real-world efficacy of ERLEADA(R) for patients with mCSPC * HORSHAM, PA - Johnson & Johnson today announcednew real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA(R) without docetaxel experienced a statistically significant 51 percent reduction in the risk of death compared to those who initiated on darolutamide without docetaxel through 24-months of follow-up (hazard ratio [HR] 0.49; 95% confidence interval [CI], 0.30-0.83; P=0.007). These findings reflecting patients treated in routine clinical practice are being presented at the 36th Annual International Prostate Cancer Update on February 2, where it was selected as a top abstract (Abstract #6).
Designed to meet rigorous FDA guidance and robust methodological framework on real-world evidence, this study included a pre-specified protocol, pre-specified primary endpoint of overall survival (OS), power calculation, and propensity score matching through inverse probability of treatment weighting (IPTW).1,2,3 Together, these methodological safeguards deliver robust, reproducible insights that inform real-world treatment decisions. The retrospective study identified mCSPC patients who initiated ERLEADA(R) or darolutamide without docetaxel between August 2022 and June 2025. There were 1,460 ERLEADA(R) patients and 287 darolutamide initiators who met study criteria.
"These real-world data show the survival benefit of apalutamide versus darolutamide in patients with mCSPC without the concurrent use of docetaxel. The results are consistent with other datasets showing similar overall survival benefit versus other commonly used agents," said Mehmet Bilen, M.D. Director, Genitourinary Medical Oncology Program, Winship Cancer Institute of Emory University.* "This real-world analysis utilized large contemporary datasets using rigorous methodology to support clinical decision-making in the absence of prospective head-to-head studies that are likely impractical to conduct."
As reported previously, ERLEADA(R) plus androgen deprivation therapy (ADT) treatment shows rapid and deep prostate-specific antigen (PSA) decline that was associated with prolonged OS.4,5 These real-world OS data build upon findings from the Phase 3 multinational, double-blinded, placebo-controlled TITAN trial, which evaluated mCSPC patients (n=1052) randomized (1:1) receiving either ERLEADA(R) 240 mg once daily (n=525) or placebo once daily (n=527).4
"Real-world comparisons can provide critical information to support patient care when conducted in a rigorous and methodologically sound manner," said Mahadi Baig, M.D., M.H.C.M., Vice President, U.S. Medical Affairs, Johnson & Johnson Innovative Medicine. "We have now seen in repeated real-world examinations the overall survival benefit of apalutamide versus other agents and this head-to-head analysis supports apalutamide being a key standard of care treatment for patients with mCSPC."
TITAN demonstrated a statistically significant OS benefit for mCSPC patients treated with ERLEADA(R) plus ADT compared to ADT alone at the primary analysis after a median 22.7 months of follow-up (HR 0.67; 95% CI, 0.51-0.89; P=0.005) and at the final analysis after a median 44 months of follow-up (HR 0.65; 95% CI, 0.53-0.79; P<0.0001).4,5 The proportion of patients alive at 24 months (92.1 percent) observed in the ERLEADA(R) cohort in this real-world analysis is generally consistent with that reported in TITAN (82.4 percent). All patients in the TITAN trial received a concomitant gonadotropin-releasing hormone agonist (GnRH) analog or had a prior bilateral orchiectomy. The dual primary endpoints were OS and radiographic progression-free survival (rPFS).
About the Study
These real-world findings adhere to the rigorous standards set by the U.S. FDA, including providing comparative effectiveness evidence from large, contemporary U.S. datasets used in routine clinical practice, peer-reviewed methods, and strict study monitoring. Complementing randomized controlled trials, real-world evidence can help inform clinical decisions, including comparative data into treatments, by collecting a plethora of data from a diverse range of patients in the real-world setting.
In this real-world analysis, both ERLEADA(R) and darolutamide were administered without docetaxel. Study investigators applied propensity score matching (PSM) to match the apalutamide and darolutamide groups through adjusting for baseline differences in measured patient characteristics. PSM is employed in observational studies to support fair comparison of outcomes.
Some limitations of this study include potential miscoding or missing information in the data sources; however, the data sources used in this study were deemed fit for purpose to identify the patient population correctly and to assess survival. IPTW, a propensity score matching statistical method, was employed to balance baseline characteristics between treatment groups, removing bias from measured confounders and replicating the conditions of a randomized clinical trial.
About Prostate Cancer
Approximately 330,000 people are diagnosed with prostate cancer each year in the U.S.6 Up to 40 percent of patients will be classified as high-risk.7 Despite advancements in treatment, disease recurrence remains substantial; up to 50 percent of patients within ten years of surgery experience recurrence and carry a significant risk of disease progression and death.7 It's estimated that more than 36,000 men will succumb to prostate cancer in 2026, which reinforces the importance of choosing the best possible therapy early for patients with advanced prostate cancer.6
About ERLEADA(R)
ERLEADA(R) (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). ERLEADA(R) received U.S. Food and Administration (FDA) approval for nmCRPC in February 2018 and received U.S. FDA approval for mCSPC in September 2019. ERLEADA(R) is the first and only next-generation androgen receptor inhibitor offering a once-daily, single-tablet treatment option for patients. To date, more than 325,000 patients worldwide have been treated with ERLEADA(R). Additional studies are ongoing in the evaluation of ERLEADA(R) for the treatment of localized high-risk or locally advanced prostate cancer including, the Phase 3 ATLAS (NCT02531516) and PROTEUS (NCT03767244) studies.
For more information, visit www.ERLEADA.com.
ERLEADA(R) IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Cerebrovascular and Ischemic Cardiovascular Events -- In a randomized study (SPARTAN) of patients with nmCRPC, ischemic cardiovascular events occurred in 3.7% of patients treated with ERLEADA(R) and 2% of patients treated with placebo. In a randomized study (TITAN) in patients with mCSPC, ischemic cardiovascular events occurred in 4.4% of patients treated with ERLEADA(R) and 1.5% of patients treated with placebo. Across the SPARTAN and TITAN studies, 4 patients (0.3%) treated with ERLEADA(R) and 2 patients (0.2%) treated with placebo died from an ischemic cardiovascular event. Patients with history of unstable angina, myocardial infarction, congestive heart failure, stroke, or transient ischemic attack within 6 months of randomization were excluded from the SPARTAN and TITAN studies.
In the SPARTAN study, cerebrovascular events occurred in 2.5% of patients treated with ERLEADA(R) and 1% of patients treated with placebo. In the TITAN study, cerebrovascular events occurred in 1.9% of patients treated with ERLEADA(R) and 2.1% of patients treated with placebo. Across the SPARTAN and TITAN studies, 3 patients (0.2%) treated with ERLEADA(R), and 2 patients (0.2%) treated with placebo died from a cerebrovascular event.
Cerebrovascular and ischemic cardiovascular events, including events leading to death, occurred in patients receiving ERLEADA(R). Monitor for signs and symptoms of ischemic heart disease and cerebrovascular disorders. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Consider discontinuation of ERLEADA(R) for Grade 3 and 4 events.
Fractures -- In a randomized study (SPARTAN) of patients with nmCRPC, fractures occurred in 12% of patients treated with ERLEADA(R) and in 7% of patients treated with placebo. In a randomized study (TITAN) of patients with mCSPC, fractures occurred in 9% of patients treated with ERLEADA(R) and in 6% of patients treated with placebo. Evaluate patients for fracture risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents.
Falls -- In a randomized study (SPARTAN), falls occurred in 16% of patients treated with ERLEADA(R) compared with 9% of patients treated with placebo. Falls were not associated with loss of consciousness or seizure. Falls occurred in patients receiving ERLEADA(R) with increased frequency in the elderly. Evaluate patients for fall risk.
Seizure -- In two randomized studies (SPARTAN and TITAN), 5 patients (0.4%) treated with ERLEADA(R) and 1 patient treated with placebo (0.1%) experienced a seizure. Permanently discontinue ERLEADA(R) in patients who develop a seizure during treatment. It is unknown whether anti-epileptic medications will prevent seizures with ERLEADA(R). Advise patients of the risk of developing a seizure while receiving ERLEADA(R) and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others.
Severe Cutaneous Adverse Reactions -- Fatal and life-threatening cases of severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) occurred in patients receiving ERLEADA(R).
Monitor patients for the development of SCARs. Advise patients of the signs and symptoms of SCARs (e.g., a prodrome of fever, flu-like symptoms, mucosal lesions, progressive skin rash, or lymphadenopathy). If a SCAR is suspected, interrupt ERLEADA(R) until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended. If a SCAR is confirmed, or for other Grade 4 skin reactions, permanently discontinue ERLEADA(R) [see Dosage and Administration (2.2)].
Interstitial Lung Disease (ILD)/Pneumonitis -- Fatal and life-threatening interstitial lung disease (ILD) or pneumonitis can occur in patients treated with ERLEADA(R).
Post-marketing cases of ILD/pneumonitis, including fatal cases, occurred in patients treated with ERLEADA(R). Across clinical trials (TITAN and SPARTAN, n=1327), 0.8% of patients treated with ERLEADA(R) experienced ILD/pneumonitis, including 0.2% who experienced Grade 3 events [see Adverse Reactions (6.1, 6.2)].
Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold ERLEADA(R) if ILD/pneumonitis is suspected. Permanently discontinue ERLEADA(R) in patients with severe ILD/pneumonitis or if no other potential causes of ILD/pneumonitis are identified [see Dosage and Administration (2.2)].
Embryo-Fetal Toxicity -- The safety and efficacy of ERLEADA(R) have not been established in females. Based on findings from animals and its mechanism of action, ERLEADA(R) can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of ERLEADA(R) [see Use in Specific Populations (8.1, 8.3)].
ADVERSE REACTIONS
The most common adverse reactions (10%) that occurred more frequently in the ERLEADA(R)-treated patients (2% over placebo) from the randomized placebo-controlled clinical trials (TITAN and SPARTAN) were fatigue, arthralgia, rash, decreased appetite, fall, weight decreased, hypertension, hot flush, diarrhea, and fracture.
Laboratory Abnormalities -- All Grades (Grade 3-4)
. Hematology -- In the TITAN study: white blood cell decreased ERLEADA(R) 27% (0.4%), placebo 19% (0.6%). In the SPARTAN study: anemia ERLEADA(R) 70% (0.4%), placebo 64% (0.5%); leukopenia ERLEADA(R) 47% (0.3%), placebo 29% (0%); lymphopenia ERLEADA(R) 41% (1.8%), placebo 21% (1.6%)
. Chemistry -- In the TITAN study: hypertriglyceridemia ERLEADA(R) 17% (2.5%), placebo 12% (2.3%). In the SPARTAN study: hypercholesterolemia ERLEADA(R) 76% (0.1%), placebo 46% (0%); hyperglycemia ERLEADA(R) 70% (2%), placebo 59% (1.0%); hypertriglyceridemia ERLEADA(R) 67% (1.6%), placebo 49% (0.8%); hyperkalemia ERLEADA(R) 32% (1.9%), placebo 22% (0.5%)
Rash -- In 2 randomized studies (SPARTAN and TITAN), rash was most commonly described as macular or maculopapular. Adverse reactions of rash were 26% with ERLEADA(R) vs 8% with placebo. Grade 3 rashes (defined as covering >30% body surface area [BSA]) were reported with ERLEADA(R) treatment (6%) vs placebo (0.5%).
The onset of rash occurred at a median of 83 days. Rash resolved in 78% of patients within a median of 78 days from onset of rash. Rash was commonly managed with oral antihistamines, topical corticosteroids, and 19% of patients received systemic corticosteroids. Dose reduction or dose interruption occurred in 14% and 28% of patients, respectively. Of the patients who had dose interruption, 59% experienced recurrence of rash upon reintroduction of ERLEADA(R).
Hypothyroidism -- In 2 randomized studies (SPARTAN and TITAN), hypothyroidism was reported for 8% of patients treated with ERLEADA(R) and 1.5% of patients treated with placebo based on assessments of thyroid-stimulating hormone (TSH) every 4 months. Elevated TSH occurred in 25% of patients treated with ERLEADA(R) and 7% of patients treated with placebo. The median onset was at the first scheduled assessment. There were no Grade 3 or 4 adverse reactions. Thyroid replacement therapy, when clinically indicated, should be initiated or dose adjusted.
DRUG INTERACTIONS
Effect of Other Drugs on ERLEADA(R) -- Co-administration of a strong CYP2C8 or CYP3A4 inhibitor is predicted to increase the steady-state exposure of the active moieties. No initial dose adjustment is necessary; however, reduce the ERLEADA(R) dose based on tolerability [see Dosage and Administration (2.2)].
Effect of ERLEADA(R) on Other Drugs
CYP3A4, CYP2C9, CYP2C19, and UGT Substrates -- ERLEADA(R) is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9 in humans. Concomitant use of ERLEADA(R) with medications that are primarily metabolized by CYP3A4, CYP2C19, or CYP2C9 can result in lower exposure to these medications. Substitution for these medications is recommended when possible or evaluate for loss of activity if medication is continued. Concomitant administration of ERLEADA(R) with medications that are substrates of UDP-glucuronosyl transferase (UGT) can result in decreased exposure. Use caution if substrates of UGT must be co-administered with ERLEADA(R) and evaluate for loss of activity.
P-gp, BCRP, or OATP1B1 Substrates -- Apalutamide is a weak inducer of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptide 1B1 (OATP1B1) clinically. Concomitant use of ERLEADA(R) with medications that are substrates of P-gp, BCRP, or OATP1B1 can result in lower exposure of these medications. Use caution if substrates of P-gp, BCRP, or OATP1B1 must be co-administered with ERLEADA(R) and evaluate for loss of activity if medication is continued.
Please see the full Prescribing Information (http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/ERLEADA-pi.pdf) for ERLEADA(R).
* * *
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Janssen Research & Development, LLC and Janssen Biotech, Inc. are Johnson & Johnson companies.
* * *
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of ERLEADA(R) (apalutamide). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
* * *
Footnotes:
*/ Dr. Bilen has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work.
1/ Considerations for the Use of Real-World Data and RealWorld Evidence to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry. U.S. Food and Drug Administration. Accessed February 2026. https://www.fda.gov/media/171667/download
2/ Emmott N, Nafie M, Hendricks-Sturrup R. Real-World Evidence to Support Causal Inference: Methodological Considerations for Non-Interventional Studies. Duke Margolis Institute for Health Policy. 2024. https://healthpolicy.duke.edu/publications/real-world-evidence-support-causal-inference
3/ Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2021;15(1):14-20. doi:10.1093/ckj/sfab158
4/ Chi KN, Agarwal, N, Bjartell, A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381(1):13-24. doi: 10.1056/NEJMoa1903307
5/ Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294-2303. doi: 10.1200/JCO.20.03488
6/ Key statistics for prostate cancer. American Cancer Society. Accessed February 2026. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
7/ Napodano G, Ferro M, Sanseverino R. High-risk prostate cancer: A very challenging disease in the field of uro-oncology. Diagnostics (Basel). 2021;11(3):400. doi: 10.3390/diagnostics11030400.
* * *
Original text here: https://www.jnj.com/media-center/press-releases/real-world-head-to-head-analysis-shows-51-reduction-in-risk-of-death-for-patients-with-metastatic-castration-sensitive-prostate-cancer-treated-with-erleada-apalutamide-versus-darolutamide-without-docetaxel-through-24-months
[Category: BizPharmaceuticals]
India's Largest DoubleTree by Hilton Opens Near Bengaluru International Airport, Marking Hilton's Eighth Hotel in the City
MCLEAN, Virginia, Feb. 3 -- Hilton Worldwide Holdings posted the following news release on Feb. 2, 2026:* * *
India's Largest DoubleTree by Hilton Opens Near Bengaluru International Airport, Marking Hilton's Eighth Hotel in the City
The 304 room hotel reflects Hilton's continued focus on expanding across India's key commercial and technology markets
*
BENGALURU, India - Hilton (NYSE: HLT) today announced the opening of DoubleTree by Hilton Bengaluru Airport, the brand's largest hotel in India. The opening joins seven Hilton hotels operating in Bengaluru and solidifies Hilton's multi brand-presence ... Show Full Article MCLEAN, Virginia, Feb. 3 -- Hilton Worldwide Holdings posted the following news release on Feb. 2, 2026: * * * India's Largest DoubleTree by Hilton Opens Near Bengaluru International Airport, Marking Hilton's Eighth Hotel in the City The 304 room hotel reflects Hilton's continued focus on expanding across India's key commercial and technology markets * BENGALURU, India - Hilton (NYSE: HLT) today announced the opening of DoubleTree by Hilton Bengaluru Airport, the brand's largest hotel in India. The opening joins seven Hilton hotels operating in Bengaluru and solidifies Hilton's multi brand-presencein the city, from luxury, full-service and focused-service offerings. Developed in partnership with Dangayach Group, the hotel brings DoubleTree by Hilton's signature warm hospitality to the city's fast-growing airport corridor, reinforcing the growing importance of Bengaluru as India's most significant commercial and technology-led market.
Located just 15 minutes from Kempegowda International Airport, the hotel is situated within the Aerospace Park, offering convenient access to major IT hubs, industrial corridors and emerging business districts. The property is the first hotel to open within the industrial and research hub, catering to the demand from corporate travellers, aviation-linked businesses and transit-led stays.
Zubin Saxena, senior vice president and regional head, South Asia, Hilton, said, "Bengaluru continues to play a central role in Hilton's growth story in India. The opening of India's largest DoubleTree by Hilton in the region underscores our confidence in the city's potential. Our focus remains on expanding thoughtfully across gateway markets with the right brands. We are grateful to our long-standing partners, Dangayach Group, whose deep local expertise has been instrumental in driving this milestone opening."
Featuring 304 carefully designed guest rooms and suites, the hotel offers three dining destinations alongside an outdoor pool with sunken cabanas, a spa and fitness centre. Rooted in DoubleTree by Hilton's warmth and welcoming hospitality, the guest experience is reflected through thoughtful touches such as the brand's signature warm chocolate chip cookie welcome on arrival, alongside inviting spaces for comfort and connection. For business and corporate gatherings, the property provides over 9,000 square feet of flexible meeting and event space, including two expansive ballrooms and multiple meeting rooms.
Vincent Ong, vice president, Full-Service Brands, Asia Pacific, Hilton, "As Hilton's fastest growing brand in India, DoubleTree by Hilton reflects the strength of our full-service portfolio, delivering feel-good moments while remaining consistent with its focus on comfort, care and connection. At DoubleTree by Hilton Bengaluru Airport, we are bringing this to life with a genuinely warm welcome, comfortable accommodations and thoughtful amenities that help guests unwind, recharge, and feel at home."
Atul Dangayach, managing director, Dangayach Group, said, "The opening of DoubleTree by Hilton Bengaluru Airport marks an important milestone for us as we bring an internationally recognised hospitality brand to Bengaluru's rapidly evolving northern corridor. Its proximity to the airport and substantial room inventory positions the hotel to support conferences, large-format meetings and transit-led stays, while its thoughtful design and amenities also cater to domestic travellers. Our continued partnership with Hilton reflects our shared vision for quality expansion and contribution to the growing hospitality demand in critical markets across India."
Food and beverage form a central pillar of the hotel, with three distinct dining outlets: Saus, the hotel's all-day dining restaurant, serves breakfast, lunch and dinner, with menus that highlight house-made marinades, relishes and seasonings, celebrating the often-overlooked elements that bring flavours together and elevate familiar favourites. Brew33, the hotel's signature lounge bar, named as a playful nod to the DoubleTree by Hilton brand (Double three), offers freshly brewed coffee and a relaxed social setting by day, transitioning into an evening lounge serving craft beers, classic cocktails and globally inspired bar snacks. For guests pressed for time, Brew33 Express offers a convenient grab-and-go coffee experience, serving freshly brewed coffee in both hot and cold brew styles. Ideal for an instant pick-me-up in the morning or a refreshing boost throughout the day, the self-service cart is thoughtfully designed for ease, efficiency, and quick access.
Hilton's portfolio includes almost 100 trading and pipeline hotels across South Asia, including 23 DoubleTree by Hilton hotels. DoubleTree by Hilton Bengaluru Airport is part of Hilton Honors, the award-winning guest-loyalty program for Hilton's world-class brands.
* * *
About Hilton
Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 26 world-class brands comprising 9,000 properties and over 1.3 million rooms, in 141 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed over 3 billion guests in its more than 100-year history. Named as the No. 1 World's Best Workplace by Great Place to Work and Fortune, Hilton aims to create the best culture for its 500,000 team members around the world. Hilton has introduced industry-leading technology enhancements to improve the guest experience, including Digital Key Share, automated complimentary room upgrades and the ability to book confirmed connecting rooms. Through the award-winning guest loyalty program Hilton Honors, the more than 235 million Hilton Honors members who book directly with Hilton can earn Points for hotel stays and experiences money can't buy. With the free Hilton Honors app, guests can book their stay, select their room, check in, unlock their door with a Digital Key and check out, all from their smartphone. Visit stories.hilton.com for more information, and connect with Hilton on Facebook, X, LinkedIn, Instagram and YouTube.
* * *
Original text here: https://stories.hilton.com/releases/indias-largest-doubletree-by-hilton-opens-near-bengaluru-international-airport
[Category: BizTravel]
Hooper, Lundy and Bookman: David Vernon to Speak at AHLA's 2026 Winter Institute
LOS ANGELES, California, Feb. 3 -- Hooper, Lundy and Bookman, a law firm, issued the following news on Feb. 2, 2026:* * *
David Vernon to Speak at AHLA's 2026 Winter Institute
David Vernon will present "Understanding Medicare Supported GME Reimbursement: Key Concepts and Policy Updates," on February 12, 2026, at American Health Law Association (AHLA)'s Winter Institute: Advising Providers and AI in Health Care.
This session will provide a comprehensive introduction to Medicare-supported Graduate Medical Education (GME), offering a strong foundation for understanding key reimbursement policies ... Show Full Article LOS ANGELES, California, Feb. 3 -- Hooper, Lundy and Bookman, a law firm, issued the following news on Feb. 2, 2026: * * * David Vernon to Speak at AHLA's 2026 Winter Institute David Vernon will present "Understanding Medicare Supported GME Reimbursement: Key Concepts and Policy Updates," on February 12, 2026, at American Health Law Association (AHLA)'s Winter Institute: Advising Providers and AI in Health Care. This session will provide a comprehensive introduction to Medicare-supported Graduate Medical Education (GME), offering a strong foundation for understanding key reimbursement policiesand touching on advanced topics critical to GME expansion at academic health systems. Attendees will explore essential concepts related to Direct GME (DGME) payments, Indirect Medical Education (IME) adjustments, full-time equivalent (FTE) caps and counting rules, and strategic opportunities to grow GME capacity. Special attention will be given to mechanisms that allow academic health systems to increase their GME caps, including Section 126 of the Consolidated Appropriations Act, 2021, and rural track programs. Participants will gain valuable insights into the structure, policy levers, and impact of Medicare GME funding, with a focus on issues relevant to academic medical center general counsel, private practitioners, and institutional decision-makers. The session will also provide updates on any new policies finalized in the year's CMS payment rules. Topics will discuss:
* Medicare's support for GME, to include DGME and IME reimbursement policies
* Key policies for Medicare GME FTE caps and FTE audits
* GME development opportunities; Section 126 of the CAA, 2021, Section 4122; and, updated Rural Track Programs
* Teaching physician reimbursement: Requirements and billing guidelines
* Strategies for Medicare GME affiliated group agreements
* GME scenarios and exemplary issues
* * *
Original text here: https://hooperlundy.com/david-vernon-to-speak-at-ahlas-2026-winter-institute/
[Category: BizLaw/Legal]
Hilton Continues Rapid Growth in Turkiye With New Signings Across Four Brands
MCLEAN, Virginia, Feb. 3 -- Hilton Worldwide Holdings posted the following news release on Feb. 2, 2026:* * *
Hilton Continues Rapid Growth in Turkiye With New Signings Across Four Brands
Further boost for Hilton's lifestyle brands which now represent nearly 20% of Hilton's Turkish pipeline, with two additional Tapestry Collection by Hilton properties slated for Istanbul
*
ISTANBUL, Turkiye - Hilton (NYSE: HLT) today announced expanded growth in Turkiye with the signings of five properties across four of its brands, building on the company's 70-year presence in the country. In addition to ... Show Full Article MCLEAN, Virginia, Feb. 3 -- Hilton Worldwide Holdings posted the following news release on Feb. 2, 2026: * * * Hilton Continues Rapid Growth in Turkiye With New Signings Across Four Brands Further boost for Hilton's lifestyle brands which now represent nearly 20% of Hilton's Turkish pipeline, with two additional Tapestry Collection by Hilton properties slated for Istanbul * ISTANBUL, Turkiye - Hilton (NYSE: HLT) today announced expanded growth in Turkiye with the signings of five properties across four of its brands, building on the company's 70-year presence in the country. In addition toproviding a further boost to Hilton's Turkish lifestyle portfolio, the signings include Antalya's first Hilton Hotels & Resorts property and further expansion for the DoubleTree by Hilton and Hilton Garden Inn brands.
Mike Collini, vice president, development, Central and Eastern Europe, Hilton, said, "Turkiye remains a key strategic market for Hilton, where we continue to see significant potential for ongoing expansion. The successful 2025 debuts of both Tapestry Collection and Canopy have reinforced the strong momentum of our lifestyle brands, reflecting travellers' growing appetite for distinctive, locally inspired experiences. Our latest signings underscore the sustained demand for Hilton's diverse offerings across the country. With a long-standing and respected presence in Turkiye, we look forward to continuing this next chapter of growth, bringing our hospitality to an even broader spectrum of travellers."
Hilton Antalya City Centre
Slated to open in 2028, Hilton Antalya City Centre will offer the signature world-class hospitality of the flagship Hilton Hotels & Resorts brand in one of Turkiye's most visited destinations. Offering 254 rooms and suites, the newbuild hotel will boast standout amenities ideal for hosting iconic gatherings of every size and a variety of occasions, including a grand ballroom, multiple meeting rooms, an expansive spa and wellness centre, indoor and rooftop pools, and diverse dining venues.
DoubleTree by Hilton Istanbul Macka
Opening this spring, DoubleTree by Hilton Istanbul Macka will bring 109 stylish rooms and suites to one of Istanbul's most sought-after neighbourhoods, steps from Nisantasi and Taksim. The hotel will feature a warm and inviting lobby lounge, all-day dining restaurant, a rooftop restaurant and bar area offering panoramic views, versatile meeting spaces, and fitness and wellness facilities. The property will offer a modern, upscale experience for travellers seeking connectivity, culture, and comfort in the city centre.
Gist Istanbul, Tapestry Collection by Hilton
Set to open in 2027, the Tapestry Collection property will introduce 46 uniquely designed rooms in one of Istanbul's most picturesque and well-connected neighbourhoods. Just steps from the Bosphorus strait, Galataport, and major transport links, the hotel will feature a restaurant and rooftop bar, as well as a fitness space for guests to use throughout their stay. With its charm and spectacular setting, the property will offer a vibrant stay for guests eager to explore the cultural and historic heartbeat of the city.
Hotel Istanbul Sisli, Tapestry Collection by Hilton
Set in the heart of Istanbul's vibrant Sisli district, Hilton Istanbul Sisli, Tapestry Collection by Hilton brings 48 stylish guest rooms to one of the city's most dynamic commercial hubs. Opening in 2028, the lifestyle property will feature a restaurant with culinary offerings inspired by the locale, two meeting rooms, and a modern fitness centre, with key shopping, culture, and transport links just moments away. Blending character, comfort, and a sense of place, the hotel will provide an authentic base for both business and leisure travellers.
Hilton Garden Inn Kocaeli Dilovasi
Hilton Garden Inn Kocaeli Dilovasi will become the city's first internationally branded hotel in the heart of the Industrial Zone when it opens in 2027. Featuring 104 contemporary guest rooms, extensive meeting space including a 500 sqm multifunction hall, a welcoming restaurant and bar, and wellness facilities such as an indoor pool, gym, and Turkish hammam, the hotel will serve as a much needed hub for business travellers, long stay guests, and corporate events in this fast growing industrial region.
In addition to these new signings, 2026 will see Hilton further strengthen the presence of its flagship brand with the opening of Hilton Istanbul Airport and the completed renovation of the iconic Hilton Istanbul Bosphorus.
Following the debut of the Tapestry Collection and Canopy by Hilton brands in Turkiye in 2025, Hilton's lifestyle portfolio is also poised for continued growth this year, with five openings scheduled. These include Hilton's first cave hotel - Elika Cave Suites Cappadocia, Curio Collection by Hilton - as well as Porto Chiara Istanbul Karakoy and Les Temps Istanbul Karakoy, both part of the Curio Collection brand. The pipeline also features Palazzo Donizetti Istanbul and Myrna Izmir Konak, each joining the Tapestry Collection brand.
Guests of all Hilton properties are able to benefit from the award-winning Hilton Honors guest loyalty programme, allowing more than 235 million members who book directly with Hilton to earn Points for hotel stays and experiences. Hilton Honors members can also unlock access to instant rewards and benefits, such as contactless check-in with room selection and exclusive member discounts.
* * *
About Hilton
Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 26 world-class brands comprising 9,000 properties and over 1.3 million rooms, in 141 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed over 3 billion guests in its more than 100-year history. Named as the No. 1 World's Best Workplace by Great Place to Work and Fortune, Hilton aims to create the best culture for its 500,000 team members around the world. Hilton has introduced industry-leading technology enhancements to improve the guest experience, including Digital Key Share, automated complimentary room upgrades and the ability to book confirmed connecting rooms. Through the award-winning guest loyalty program Hilton Honors, the more than 235 million Hilton Honors members who book directly with Hilton can earn Points for hotel stays and experiences money can't buy. With the free Hilton Honors app, guests can book their stay, select their room, check in, unlock their door with a Digital Key and check out, all from their smartphone. Visit stories.hilton.com for more information, and connect with Hilton on Facebook, X, LinkedIn, Instagram and YouTube.
* * *
About Hilton Hotels & Resorts
For over a century, Hilton Hotels & Resorts has set the benchmark for hospitality around the globe, connecting people, cultures and communities. Offering striking design and vibrant communal spaces--from buzzing lobbies to lively bars, best-in-class restaurants, and iconic gatherings-- Hilton Hotels & Resorts is the place to see and be seen in the world's most sought-after destinations. With more than 600 hotels across six continents, Hilton Hotels & Resorts is where the world comes together, and travelers are masterfully hosted with expertise and care. Experience a legendary stay at Hilton Hotels & Resorts by booking at hiltonhotels.com or through the industry leading Hilton Honors app. Hilton Honors members who book directly through preferred Hilton channels have access to instant benefits. Learn more about Hilton Hotels & Resorts at stories.hilton.com/hhr, and follow the brand on Facebook, X and Instagram.
* * *
About DoubleTree by Hilton
DoubleTree by Hilton is a fast-growing, global portfolio of more than 700 hotels across 61 countries and territories. For more than 55 years, DoubleTree by Hilton has continued to be a symbol of comfort for business and leisure travelers around the world, welcoming guests with the beloved DoubleTree chocolate chip cookie and prioritizing the spaces and human moments that make travelers feel good. DoubleTree by Hilton offers contemporary accommodations and amenities, including unique food and beverage experiences, state-of-the-art fitness offerings and meetings and events spaces. Experience a comfortable stay at DoubleTree by Hilton by booking at doubletree.com or through the industry-leading Hilton Honors app. Hilton Honors members who book directly through preferred Hilton channels have access to instant benefits. Learn more about DoubleTree by Hilton at stories.hilton.com/doubletree, and follow the brand on Facebook, X and Instagram.
* * *
About Tapestry Collection by Hilton
Tapestry Collection by Hilton is a portfolio of more than 180 independent hotels each with an original, vibrant personality, encouraging guests to enjoy off-the-beaten-path experiences in destinations worth exploring. While each property has a unique story to share that comes to life through uplifting design and unique food & beverage, every Tapestry Collection property is united by the reliability that comes with the Hilton name, in addition to the benefits of the award-winning Hilton Honors program. Experience Tapestry Collection by Hilton by booking at tapestrycollectionbyhilton.com or through the industry-leading Hilton Honors app. Hilton Honors members who book directly through preferred Hilton channels have access to instant benefits. Learn more about Tapestry Collection by Hilton at stories.hilton.com/tapestry, and follow the brand on Facebook, Instagram and X.
* * *
About Hilton Garden Inn
The award-winning Hilton Garden Inn brand provides business and leisure guests upscale, affordable accommodations and modern amenities for an experience that is simply on another level. The Hilton Garden Inn Promise affirms the brand's goal to make each guest's stay better and brighter. Guaranteed. With more than 1,100 hotels in 65 countries and territories around the world, the brand ensures today's busy travelers have a bright and satisfying experience, starting with the first hello. Hilton Garden Inn brightens the stay experience with an array of culinary offerings that are tailored to regional tastes and preferences, providing an elevated and unique dining experience at each location. Experience a positive stay at Hilton Garden Inn by booking at hiltongardeninn.com or through the industry-leading Hilton Honors app. Hilton Honors members who book directly through preferred Hilton channels have access to instant benefits. Learn more about Hilton Garden Inn at stories.hilton.com/hgi, and follow the brand on Facebook and Instagram.
* * *
Original text here: https://stories.hilton.com/releases/hilton-continues-rapid-growth-in-turkiye-new-signings-across-four-brands
[Category: BizTravel]
GE Vernova Completes Prolec GE Acquisition, Accelerating Electrification Segment Growth Trajectory
CAMBRIDGE, Massachusetts, Feb. 3 -- G.E. Vernova, an energy company, posted the following news release on Feb. 2, 2026:* * *
GE Vernova completes Prolec GE acquisition, accelerating Electrification segment growth trajectory
* Milestone further positions GE Vernova as a global leader serving growing grid markets by expanding its presence and support in North America
* Prolec GE and its affiliates will go to market as GE Vernova, operating within the Electrification segment
* Transaction is immediately accretive and now reflected in GE Vernova's latest 2026 financial guidance and outlook by ... Show Full Article CAMBRIDGE, Massachusetts, Feb. 3 -- G.E. Vernova, an energy company, posted the following news release on Feb. 2, 2026: * * * GE Vernova completes Prolec GE acquisition, accelerating Electrification segment growth trajectory * Milestone further positions GE Vernova as a global leader serving growing grid markets by expanding its presence and support in North America * Prolec GE and its affiliates will go to market as GE Vernova, operating within the Electrification segment * Transaction is immediately accretive and now reflected in GE Vernova's latest 2026 financial guidance and outlook by2028
*
GE Vernova Inc. (NYSE: GEV) today announced it has completed the acquisition of the remaining 50% stake of Prolec GE, its former unconsolidated joint venture with Xignux ("Prolec GE"). The transaction, originally announced in October 2025, closed following receipt of all required regulatory approvals, for a purchase price of $5.275 billion, funded as previously disclosed with an equal mix of cash and debt.
Prolec GE is an electric industry leader in North America, with approximately 10,000 employees across seven manufacturing sites in the Americas, including five in the U.S. It produces a wide variety of transformers and transformer components for the generation, transmission and distribution of electricity, complemented by its broad transformer services offering. This acquisition consolidates Prolec GE after 30 years of partnership as a joint venture.
"We're excited to reach this important milestone with our first sizable acquisition as a standalone public company and welcome the Prolec GE team into GE Vernova," said GE Vernova CEO Scott Strazik. "We are building on a decades-long partnership and combining the strengths of our two companies to offer customers a broader portfolio and operate at a higher capacity to fulfill expectations, especially in North America where grid demand is strong. As we continue to focus on our mission to electrify to thrive and decarbonize the world, this acquisition will play a critical role in driving our sustained growth in Electrification."
Prolec GE will go to market as GE Vernova and operate within GE Vernova's Electrification segment. The deal is immediately accretive before synergies and is expected to drive additional profitable growth for GE Vernova, which is now reflected in GE Vernova's latest 2026 financial guidance and outlook by 2028.
"Our customers are asking for more capacity from the grid," said GE Vernova Electrification CEO Philippe Piron. "With Prolec GE now fully part of GE Vernova, we are better equipped to respond to that demand and better serve our installed base, utilizing our combined manufacturing footprint for transformers and a strong pipeline of innovation to serve the electrification needs of the world. Our priority from day one is a smooth integration, where customers continue to receive the service and quality they expect, supported by the scale of the combined Prolec GE and GE Vernova teams."
GE Vernova will retain the current leadership across Prolec GE, with Ricardo Suarez remaining in his role as Prolec GE CEO reporting to Philippe Piron.
"Joining GE Vernova as a fully integrated business is a natural next step in our journey after years of partnership," said Prolec GE CEO Ricardo Suarez. "We are proud of our strong culture and the legacy we've built, and as part of the one GE Vernova family, we will adapt and embrace the GE Vernova Way while maintaining the local culture, heritage and identity that made us who we are today. I am excited for the opportunities our employees will have to learn and grow further as part of a global industry leader, the continued investment in our sites, and an even stronger capability to serve our customers across North America."
* * *
Forward-Looking Statements
This press release contains forward-looking statements - that is, statements related to future events that by their nature address matters that are, to different degrees, uncertain, such as statements about GE Vernova's expected future business and financial performance and financial condition following the closing of the Prolec GE acquisition, the impact of such acquisition and the results it may generate or produce, and the timing of such impact and results, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "see," "will," "would," or "estimate". Forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from current expectations. These risks, uncertainties, and factors include those discussed in our most recent Annual Report on Form 10-K, as may be updated from time to time in our filings with the SEC and as posted on our website at www.gevernova.com/investors/fls. GE Vernova does not undertake any obligation to update or revise its forward-looking statements except as required by law or regulation.
* * *
About GE Vernova
GE Vernova Inc. (NYSE: GEV) is a purpose-built global energy company that includes Power, Wind, and Electrification segments and is supported by its accelerator businesses. Building on over 130 years of experience tackling the world's challenges, GE Vernova is uniquely positioned to help lead the energy transition by continuing to electrify the world while simultaneously working to decarbonize it. GE Vernova helps customers power economies and deliver electricity that is vital to health, safety, security, and improved quality of life. GE Vernova is headquartered in Cambridge, Massachusetts, U.S., with approximately 85,000 employees across approximately 100 countries around the world.
Supported by the Company's purpose, The Energy to Change the World, GE Vernova technology helps deliver a more affordable, reliable, sustainable, and secure energy future.
GE Vernova currently employs approximately 20,000 people in the United States of America across all 50 states. With more than 129 years of experience in Mexico, GE Vernova today employs over 1,700 people across five sites, and its equipment provides 38 GW of electricity generating capacity--nearly 42% of the country's total--through advanced technologies including eight HA gas turbines, the Laguna Verde nuclear plant, and one of the world's largest fleets of F-class gas turbines.
* * *
Original text here: https://www.gevernova.com/news/press-releases/ge-vernova-completes-prolec-ge-acquisition
[Category: BizEnergy]
Fredrikson Partners With 2026 Special Olympics USA Games
MINNEAPOLIS, Minnesota, Feb. 3 -- Fredrikson and Byron, a law firm, issued the following news:* * *
Fredrikson Partners with 2026 Special Olympics USA Games
Fredrikson proudly announces its platinum level partnership with the 2026 Special Olympics USA Games, scheduled to take place in Minneapolis this June. As a sponsor of the upcoming USA Games, Fredrikson will help to create an unforgettable experience for athletes, fans and volunteers in the week-long, world-class event.
"Our partnership with the 2026 Special Olympics USA Games started with the incredible work of our lawyers and lobbyists ... Show Full Article MINNEAPOLIS, Minnesota, Feb. 3 -- Fredrikson and Byron, a law firm, issued the following news: * * * Fredrikson Partners with 2026 Special Olympics USA Games Fredrikson proudly announces its platinum level partnership with the 2026 Special Olympics USA Games, scheduled to take place in Minneapolis this June. As a sponsor of the upcoming USA Games, Fredrikson will help to create an unforgettable experience for athletes, fans and volunteers in the week-long, world-class event. "Our partnership with the 2026 Special Olympics USA Games started with the incredible work of our lawyers and lobbyistsin the initial bid to bring the event to Minnesota," said Fredrikson president Melodie Rose. "Our longstanding commitment of service to our community has always been a pillar of our firm's culture and we are ecstatic to champion this inspiring event which celebrates community, inclusion and the joy of togetherness."
"It is an honor to support the team to ensure legal best practices are maintained across the organization and 2026 USA Games," said Fredrikson shareholder Travis Anderson, offering both his legal acumen and a commitment to inclusion through his role as board member and Director and General Counsel for the 2026 USA Games. Anderson's involvement with the Special Olympics spans decades, and his current board role is a four-year term.
Fredrikson lawyers and staff have provided critical legal support to Special Olympics Minnesota and the 2026 Special Olympics USA Games. The work included lobbying for the event's location, held every four years, to be in Minneapolis, and will continue throughout the week of the USA Games with a firmwide initiative to rally volunteers from across Fredrikson, including clients, staff and their families and friends.
"We are deeply grateful to Fredrikson for their partnership with the USA Games," stated Christy Sovereign, CEO of the 2026 Special Olympics USA Games. "Beyond their ongoing commitment to our mission, they are an essential member of the Local Organizing Committee and a guiding force in our operations. Their strategic leadership, legal expertise and investment of time and resources have strengthened our capacity tenfold in delivering a world-class event and an extraordinary experience for athletes, families and fans."
"To see this monumental event brought to Minneapolis is such a special opportunity for our state," said Fredrikson shareholder Chantal Wilson, Special Olympics Minnesota board member. "There is a place for everyone at this event. We look forward to cheering on the athletes and seeing Minnesota shine."
The 2026 Special Olympics USA Games - scheduled for June 20-26, 2026, across Minnesota's Twin Cities with sports competitions at the University of Minnesota and the National Sports Center in Blaine - is a national celebration of inclusivity, changing perceptions and the ability of the human spirit rising above limitations. The USA Games, with co-presenting partners Jersey Mike's Subs and UnitedHealthcare, will be one of the biggest U.S. sporting events of the year, drawing tens of thousands of fans to celebrate the ability of nearly 3,000 incredible athletes from all 50 states as they compete in 16 Olympic-type team and individual sports. As a state with a long history of championing inclusion, the USA Games now bring an unrivaled opportunity to Minnesota to spark new energy around the Special Olympics movement and create a lasting legacy of positive change. Learn more about the Games and how you can get involved on their website (https://2026specialolympicsusagames.org/).
* * *
Fredrikson & Byron is a leading Midwest law firm working collaboratively to help businesses achieve their goals regionally, nationally and globally. With a reputation as the firm "where law and business meet," our attorneys bring business acumen and entrepreneurial thinking to work with clients and operate as business advisors and strategic partners as well as legal counselors. The firm's 400+ attorneys are based in Minneapolis, with offices in Ames, Bismarck, Des Moines, Fargo, Madison, Mankato, St. Paul, Saltillo, Mexico, and Shanghai, China. Learn more at fredlaw.com or LinkedIn.
* * *
Original text here: https://www.fredlaw.com/news-fredrikson-partners-with-2026-special-olympics-usa-games
[Category: BizLaw/Legal]
Cesc Gay's New Film Premieres March 27 on Netflix
LOS GATOS, California, Feb. 3 -- Netflix, a content provider, issued the following news on Feb. 2, 2026:* * *
Cesc Gay's New Film Premieres March 27 on Netflix
Netflix announced today the release date and first images of 53 Sundays, the adaptation of the play of the same name by Cesc Gay (My Friend Eva, The People Upstairs, Truman), who also wrote and directed the film. 53 Sundays will premiere globally on Netflix on March 27.
Starring Javier Camara, Carmen Machi, Javier Gutierrez, and Alexandra Jimenez, the film is a dramatic comedy that tells the story of three siblings who get together ... Show Full Article LOS GATOS, California, Feb. 3 -- Netflix, a content provider, issued the following news on Feb. 2, 2026: * * * Cesc Gay's New Film Premieres March 27 on Netflix Netflix announced today the release date and first images of 53 Sundays, the adaptation of the play of the same name by Cesc Gay (My Friend Eva, The People Upstairs, Truman), who also wrote and directed the film. 53 Sundays will premiere globally on Netflix on March 27. Starring Javier Camara, Carmen Machi, Javier Gutierrez, and Alexandra Jimenez, the film is a dramatic comedy that tells the story of three siblings who get togetherto decide what to do with their 86-year-old father, who has begun to exhibit strange behavior. Should they take him to a nursing home? Should he go live with one of them? What begins as a polite family gathering turns into a situation that is as funny as it is unexpected and spirals out of control.
The film is produced by Imposible Films, with Marta Esteban and Laia Bosch as executive producers. Written and directed by Cesc Gay, 53 Sundays was shot at Netflix Production Center in Tres Cantos and various locations in central Madrid.
In the words of Cesc Gay, "I have always been very fortunate to work with actors and actresses who have made my work better. Comedy is the most difficult genre, but from the first rehearsals my fears disappeared when I heard Javier Camara, Carmen Machi, Javier Gutierrez, and Alexandra Jimenez read the script. During those breakfasts at my apartment in Madrid, we talked, discussed, rehearsed, laughed, and, between the five of us, we shaped this comedy that audiences will soon be able to enjoy in their homes."
* * *
About Imposible Films
Imposible Films is a production company from Barcelona that was founded in 2000, with a solid track record in auteur cinema. It has produced all of Cesc Gay's films, including award-winning titles such as Truman and Sentimental.
* * *
Original text here: https://about.netflix.com/en/news/cesc-gays-new-film-premieres-march-27-on-netflix
[Category: Media]